FGF21 and metabolic dysfunction-associated steatotic liver disease: A number of publications showed significantly higher serum concentrations of FGF-21 in a population of patients with NAFLD compared to the controls (Yilmaz et al., 2010a, Yilmaz et al., 2010b, Giannini et al., 2013).